Amedisys (NASDAQ:AMED) Earns Buy Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Amedisys (NASDAQ:AMEDGet Free Report) in a report issued on Sunday. The brokerage set a “buy” rating on the health services provider’s stock.

A number of other research firms have also recently weighed in on AMED. Raymond James reiterated a “market perform” rating on shares of Amedisys in a research note on Tuesday, March 26th. Royal Bank of Canada boosted their target price on shares of Amedisys from $97.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 25th. Seven analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Amedisys currently has a consensus rating of “Hold” and an average target price of $97.50.

Read Our Latest Research Report on AMED

Amedisys Stock Down 0.3 %

AMED opened at $92.16 on Friday. The company has a quick ratio of 1.05, a current ratio of 1.05 and a debt-to-equity ratio of 0.32. The stock has a market cap of $3.01 billion, a price-to-earnings ratio of -297.29, a PEG ratio of 4.35 and a beta of 0.86. Amedisys has a twelve month low of $71.19 and a twelve month high of $96.44. The company’s 50-day moving average price is $93.51 and its two-hundred day moving average price is $93.59.

Amedisys (NASDAQ:AMEDGet Free Report) last released its earnings results on Wednesday, February 21st. The health services provider reported $0.94 earnings per share for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.10). The company had revenue of $570.79 million during the quarter, compared to analysts’ expectations of $566.85 million. Amedisys had a negative net margin of 0.44% and a positive return on equity of 12.76%. The firm’s revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.16 earnings per share. As a group, equities analysts expect that Amedisys will post 4.54 earnings per share for the current year.

Institutional Trading of Amedisys

Hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC increased its holdings in Amedisys by 181.1% during the 4th quarter. SG Americas Securities LLC now owns 63,953 shares of the health services provider’s stock worth $6,079,000 after acquiring an additional 41,206 shares during the period. Bank of Nova Scotia bought a new stake in Amedisys during the 3rd quarter worth approximately $26,671,000. Hsbc Holdings PLC increased its holdings in Amedisys by 184.9% during the 3rd quarter. Hsbc Holdings PLC now owns 110,479 shares of the health services provider’s stock worth $10,327,000 after acquiring an additional 71,705 shares during the period. Clear Street Markets LLC bought a new stake in Amedisys during the 3rd quarter worth approximately $1,252,000. Finally, UBS Group AG increased its holdings in Amedisys by 336.5% during the 3rd quarter. UBS Group AG now owns 42,301 shares of the health services provider’s stock worth $3,951,000 after acquiring an additional 32,610 shares during the period. Institutional investors own 94.36% of the company’s stock.

About Amedisys

(Get Free Report)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Read More

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.